Topic
Moderna
Moderna and Merck mRNA melanoma vaccine cuts recurrence risk by 42 percent
A personalized mRNA cancer vaccine developed by Moderna and Merck significantly reduces melanoma recurrence risks, according to landmark Phase 3 clinical trial results.
Moderna's melanoma vaccine meets primary goal, sparks growth hopes
Moderna's personalized mRNA cancer vaccine Intismeran met its primary endpoint in a late-stage trial combined with Merck's Keytruda, sparking a major market rally.